T he classic phenotype of cystic fibrosis (CF) in the digestive system includes malabsorption of fats. Fat malabsorption can result in a suboptimal nutritional status, thereby contributing to recurrent pulmonary infections in patients with CF (1) . Therefore, the improvement of fat absorption is an important key feature in CF care. Pancreatic insufficiency is the main cause of fat malabsorption in the majority of patients with CF. Although fat absorption is greatly improved by pancreatic enzyme replacement therapy, it still remains 10-30% lower than normal in a substantial fraction of patients (2) . Other causes of fat malabsorption may be a decrease in intestinal pH, intestinal mucosal abnormalities (such as small intestinal bacterial overgrowth (SIBO), viscous mucus, and intestinal inflammation), or changes in biliary bile salt composition and/or the enterohepatic circulation of bile salts (2) .
Treatment strategies other than pancreatic enzyme substitution should be developed so as to further improve fat absorption in patients with CF. Two previous studies indicated a positive effect of antibiotics (AB) treatment on nutritional status in CF conditions. Patients with CF showed improvements in body weight and BMI after 6 months of treatment with azithromycin, irrespective of changes in pulmonary function (3, 4) . It is unclear which of the properties of azithromycin-antimicrobial or anti-inflammatory-brought about this result. CF transmembrane conductance regulator (CFTR)-knockout mice showed increases in body weight after a 3-week treatment with broadspectrum AB, as compared with controls (5) . This may reflect effective treatment of SIBO, which is a common feature in CF conditions (2) and is known to respond well to AB treatment in CFTR-knockout mice (5) . Because intestinal bacteria are able to deconjugate bile salts, they could impair the solubilization capacity of bile (6) , thereby contributing to fat malabsorption in patients with CF.
CF mice are generally pancreas-sufficient, and yet they have problems with fat absorption (7) . In this regard, CF mice mimic the condition in human patients with CF who are receiving treatment with pancreatic enzymes (thereby being rendered pancreas-sufficient). The CF mouse model is therefore an excellent one in which to study fat malabsorption caused exclusively by the intestinal CF phenotype. CFTR-knockout mice have a severe intestinal phenotype, and have lower fat absorption percentages in comparison with wild-type (WT) animals. CFTR homozygous ΔF508 mice, the model for the most common mutation found in CF patients, display a milder intestinal phenotype. These latter CF mice have a delayed intestinal absorption of fatty acids, as we previously demonstrated by absorption kinetics with isotope-labeled fats (7) .
We aimed to determine the effect of broad-spectrum AB treatment on fat absorption in both CFTR-knockout mice and homozygous ΔF508 mice. We also analyzed small-intestinal Table 1 shows the nutritional data of homozygous ΔF508 mice (Δ/Δ), CFTR-knockout mice (−/−), and their WT littermates (+/+) after AB or control treatment. AB treatment did not improve body weight in Δ/Δ mice. As seen in a previous study (5) , body weight increased in the male −/− mice as compared with untreated controls (+24%, P = 0.02). In our study, there were not enough female −/− mice for this analysis. The multiple-regression analysis showed that AB had a beneficial effect on body weight in the male mice of both genetic backgrounds irrespective of the CF phenotype (C57BL/6 mice: r 2 = 0.7, P = 0.02, FVB/129 mice: r 2 = 0.9, P = 0.01). Parameters for fat absorption were not dependent on gender (Tables 2 and 3) .
AB Treatment Did Not Improve Fat Absorption
In accordance with the results from previous studies (7), the total absorption of dietary fat was quantitatively similar in Δ/Δ mice and +/+ mice and was not enhanced by AB treatment ( Table 1) . Total fat absorption was ~4% lower in the −/− mice than in the +/+ mice, and this did not improve after AB (Figure 1a) . Detailed analysis showed no changes in the absorption of saturated fatty acids in either the Δ/Δ mice or the −/− mice (Figure 1b-c) . In both CF mouse models, AB did not improve the absorption of unsaturated fatty acids (controltreated Δ/Δ mice: 92% ± 1% vs. AB-treated Δ/Δ mice: 93% ± 1%, P = 0.4 and control-treated −/− mice: 99% ± 1% vs. AB-treated −/− mice: 98% ± 1%, P = 0.6).
AB Treatment Accelerated the Absorption of Fatty Acids in Homozygous ΔF508 and WT Mice
Given that Δ/Δ mice have delayed fatty acid uptake (7), we also assessed the effect of AB on the kinetics of fat absorption (Figure 2) . After AB treatment, a trend toward higher uptake was observed in Δ/Δ mice as compared with +/+ mice. Of interest, the total plasma appearance (area under the curve) of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C-palmitic acid and 1-13 C-stearic acid was higher in AB-treated Δ/Δ and +/+ mice (P = 0.04) than in control mice, compatible with an AB effect independent of CF phenotype (Tables 4 and 5, respectively). The ratio of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C-palmitic acid to 1-13 C-stearic acid was similar among the groups for all time points, indicating that the accelerated absorption was attributable to long-chain fatty acids (LCFAs) uptake and not to accelerated lipolysis. Total plasma triglycerides were similar among the groups (data not shown).
Homozygous ΔF508 Mice Do Not Exhibit SIBO
As previously reported, the −/− mice displayed SIBO, and these bacteria were markedly reduced after AB (5) (data not shown). We analyzed the data to determine whether the Δ/Δ mice also had SIBO. We found that the total bacterial load was similar in the small intestines of the Δ/Δ and +/+ mice, and did not change after AB treatment (Figure 3) . Given that certain bacterial species can modulate bile acid metabolism and influence fat absorption (8) , and allowing for the possibility that the bacterial composition might change after 3 weeks of oral AB, we additionally analyzed different subgroups of bacteria ( Table 6 ). We did not find Nutritional data of homozygous ΔF508 mice (∆/∆) (FVB/129 genetic background), cFTR-knockout mice (−/−) (c57Bl/6/129 genetic background), and wild-type littermates (+/+) after aB or control treatment. except for body weight in the aB-treated −/− mice, no differences were observed between the aB and control-treated mice of the same genetic background (Mann-Whitney test). The ingested amount of aB was similar between all groups (Kruskal-Wallis test). Values are depicted as mean ± sD.
aB, antibiotic; c, ciprofloxacine; cFTR, cystic fibrosis transmembrane conductance regulator; LcT, long-chain triglycerides; M, metronidazole.
*P < 0.05.
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a change in bacterial composition in either the Δ/Δ or the +/+ mice after AB treatment. As previously reported in the case of AB-treated mice (9) , AB significantly increased the weight of the cecum in both Δ/Δ and +/+ mice relative to controls (controls: 296 ± 99 mg, AB: 489 ± 190 mg, P = 0.03) and also the length of the cecum (controls: 2.8 ± 0.3 cm, AB: 3.6 ± 0.7 cm, P = 0.02) (Figure 4 ).
AB Treatment Tended to Normalize Bile Salt Composition in Gallbladders of Homozygous ΔF508 Mice
We analyzed the bile salts in gallbladder bile of the Δ/Δ and +/+ mice to determine whether the accelerated absorption of fatty acids after AB treatment could be attributable to an improvement in the solubilization capacity of bile. In accord with the results of previous studies (10), the contribution of the primary bile salt cholic acid (CA) in gallbladder bile was found to be higher in the Δ/Δ mice (Δ/Δ: 68% ± 3%, +/+: 44% ± 1%, P = 0.04) ( Figure 5 ). AB reduced the percentage contribution of CA and increased the percentage contribution of β-muricholic acid, resulting in a more hydrophilic bile salt composition in the AB-treated Δ/Δ mice (Heuman index: −0.28 ± 0.1 for AB-treated vs. −0.59 ± 0.09 for control-treated Δ/Δ mice, P = 0.03). Because hydrophobic bile salts are better able to solubilize lipids than hydrophilic bile salts are, the accelerated fatty acid uptake cannot be explained on the basis of changes in bile salt composition.
AB Treatment Reduced Fecal CA Excretion in Homozygous ΔF508 and CFTR-Knockout Mice
CF mice as well as human patients with CF have increased excretion of fecal bile salts (2, 11) . AB treatment did not significantly change the fecal excretion of total bile salts in Δ/Δ or −/− mice (−40% in both CF mouse models, P = 0.06). However, in comparison with controls, AB reduced the excretion of CA by ~50% in Δ/Δ and −/− mice (P = 0.04, Figure 6 ). In all AB-treated mice, the fecal excretion of the "classic" secondary bile salts deoxycholic acid and ω-muricholic acid was reduced, whereas the fecal excretion of hyodeoxycholic acid was increased.
AB Treatment Reduced mRNA Expression of Muc2 in the Small Intestines of Homozygous ΔF508 Mice
A reduction in mRNA expression of mucin 2 was observed after AB treatment in Δ/Δ mice (AB-treated: 0.51 ± 0.06 vs. 0.96 ± 0.30 control-treated, P = 0.02).
DiSCUSSioN
It has been previously shown that AB treatment eradicates SIBO and increases body weight in CFTR-knockout mice (5). 
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Our study adds the important finding that the positive effect of AB on body weight is not mediated by increasing the absorption of long-chain triglycerides. AB treatment of homozygous ΔF508 mice without SIBO neither augmented body weight nor increased fat absorption. Collectively, the data indicate that the positive effect of AB on body weight in CFTR-knockout mice may be attributable to the treatment of SIBO and not to enhanced absorption of long-chain triglycerides. The improved nutritional status that was observed in the CFTR-knockout mice could possibly be explained in terms of other AB-related effects. It has previously been reported that AB effects on the small intestine in CFTR-knockout mice (reduction in bacterial load, inflammation, and mucus) can decrease energy demand and thereby improve nutritional status (12) (13) (14) . Given that these intestinal mucosal abnormalities may also (theoretically) impair the uptake of proteins and carbohydrates, we cannot exclude the possibility that the absorption of these macronutrients also improved after AB treatment. However, we do not have indications that their absorption is suboptimal in CF mice. Malabsorption of medium-chain triglycerides is almost completely corrected after pancreatic enzyme replacement therapy in human patients with CF (15) . Therefore, medium-chain triglyceride malabsorption is not likely to contribute to fat malabsorption in the pancreatic-sufficient CF mice in our study. A decrease in energy requirement is the most likely explanation for the improved body weight. To what extent the previous reported effects of AB on the intestine decreased the energy demand, and whether these changes are inversely related to body weight, remain to be evaluated. In veterinary medicine, several AB are used as growth promoters, and these are probably mediated through suppression of Gram-positive intestinal bacteria (16) . Of interest, our multiple-regression analysis revealed that the effect of AB treatment on bacterial growth was gender-related, whereas none of the other parameters (e.g., bacterial classes in the small intestine (data not shown), fat absorption) were Articles Wouthuyzen-Bakker et al.
gender-related. There is no mechanism-based explanation for the observed effect. AB accelerated LCFA uptake in homozygous ΔF508 mice as well as in WT mice. The anticipated coefficient of variation of 10% was higher than expected, which may explain why there was significantly accelerated uptake of LCFA in the AB-treated animals (WT plus ΔF508), whereas the rate of increase of uptake was not significant in the ΔF508 mice group alone. The mechanism through which AB increase the plasma levels of orally administered fat is unclear. Given that AB did not alter the gallbladder bile salt composition in WT mice, and also did not change the major subclasses of bacteria in the small intestine, these factors probably do not contribute to the changes in fat absorption kinetics. Also, the fact that accelerated fatty acid uptake was observed in both CF and WT mice suggests an aspecific treatment effect on intestinal physiology, for example, on intestinal transit time, mucus composition, or the unstirred water layer. It has been previously shown that AB prolong the transit time in the small intestine in WT mice (13) . The authors of the study hypothesized that normal microflora might play an important role in the regulation of intestinal transit time (13) . Given that homozygous ΔF508 mice have the same intestinal flora as WT, it is possible that intestinal transit is prolonged in ΔF508 mice also, thereby enhancing intestinal fatty acid uptake. In addition, AB-induced bile flow is described in relation to some AB, and this should be considered as a possible underlying mechanism (17) . The biological significance of the changes in fatty acid kinetics remains to be determined. One could speculate that a reduction in the rate of fatty acid absorption indicates a more rate-limiting milieu in the small intestinal lumen, and a more gradual appearance of the dietary fat into the circulation. Whereas for carbohydrates the rate of appearance into the circulation is clearly associated with metabolic effects ("slow and rapid carbohydrates"), the corresponding effects of fat absorption rates remain largely unexplored. In the homozygous ΔF508 mice, the decreased rate of uptake is adequately compensated for by an increase in the absorption capacity of the small intestine, resulting in a normal overall fat absorption. This compensatory capacity may be insufficient in patients with CF, in whom other phenomena also contribute to fat malabsorption (e.g., impaired lipolysis because of pancreatic insufficiency) or where more overt fat malabsorption 
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is present. This concept is especially interesting, because AB treatment has been shown to increase fat absorption by ~20% in premature (non-CF) infants with overt fat malabsorption (18) . Future studies in this area would lead to a better understanding of the exact role of AB in the absorption kinetics and/ or absorption of fat.
AB treatment decreased fecal CA excretion in both CF mouse models. Our observation corresponds to the findings of an earlier report in patients with CF. In that study, a 7-day treatment with metronidazole reduced fecal bile salt excretion by ~30% in three of four CF patients (11) . Some studies have suggested that AB may have an inhibitory effect on bile salt synthesis in the liver (19, 20) ; this raises the possibility that the decrease in fecal CA is merely because of a reduced synthesis. Although we found a decrease in the percentage Articles Wouthuyzen-Bakker et al.
contribution of CA in the bile of AB-treated homozygous ΔF508 mice, this effect was not observed in WT animals. Therefore, we consider it more likely that the decrease in biliary CA is explained by a reduction in the synthesis of CA secondary to increased intestinal absorption. Fecal excretion of orally administered 24-[ 14 C] CA decreased after AB treatment in human patients with CF (21) . Our data therefore suggest an improved enterohepatic circulation of CA. Although we did not perform histology on the small intestine, we found a reduced mRNA expression of Muc2, a structural component of the intestinal mucus layer, in agreement with findings of previous studies in CFTR-knockout mice (12) . We consider it unlikely that intestinal transit time could explain the observed changes in fecal bile salt excretion. The reduction in fecal excretion of CA in CFTR-knockout mice was similar to the reduction in the homozygous ΔF508 mice, whereas (as previously indicated) AB did not change intestinal transit time in the CFTR-knockout mice (13) . We found that the levels of the "classic" secondary bile salts such as deoxycholic acid and ω-muricholic acid were reduced in the AB-treated animals. Of interest, however, the level of hyodeoxycholic acid (formed by 7β-hydroxylation) increased. Given that only certain strains of bacteria are capable of 7β-hydroxylation, it seems reasonable to assume that this shift in secondary bile salt formation is caused by AB-induced changes in bacterial colonization in the colon (8) .
In conclusion, we showed that the growth-enhancing effect of AB treatment in CFTR-knockout mice is not attributable to increased fat absorption. AB treatment accelerates fatty acid absorption in both homozygous ΔF508 and WT mice and partially corrects the increased fecal excretion of bile salts in both CF mouse models. The potential therapeutic effect of AB on these parameters needs to be further explored, both in CF and in non-CF conditions.
METHoDS
Mice and Diet CFTR tm1Unc
-knockout mice with a C57BL/6 genetic background (n = 17) and WT littermates (n = 17) were reared in an environmentally controlled facility at the University of Kansas Medical Center. From the age of 10 days, the mice were maintained on a complete elemental liquid diet to prevent lethal intestinal obstruction (Peptamen; Nestlé, Deerfield, IL). The liquid diet contained 33% energy derived from fat (23% of mediumchain triglycerides and 10% of long-chain triglycerides). The LCFAs in the diet were composed of: 16.4 mol% palmitic acid, 6.7 mol% stearic acid, 22.2 mol% oleic acid, 43.6 mol% linoleic acid, 4.6 mol% α-linolenic acid, 0.1 mol% arachidonic acid, and 0.06 mol% docosahexaenoic acid. The experiment started when the animals were 3 weeks of age, and was performed as previously described (5) . CFTR tm1Eur homozygous ΔF508 mice with an FVB/129 genetic background (n = 8) and WT littermates (n = 8) were reared in an environmentally controlled facility at the Erasmus Medical Center (Rotterdam, the Netherlands). The mice had free access to water and a standard semisynthetic chow diet (Hope Farms, Woerden, the Netherlands). The diet contained 13% energy derived from fat. The LCFA composition was similar to that in the liquid diet. The experiment was performed in mice between 8 and 11 weeks of age. Except for the CFTR-knockout mice in the control-treated group (male, n = 4), both genders were equally represented in the groups after randomization. Except for body weight, no gender-related differences between parameters were observed.
The experimental protocols were approved by the University of Kansas Medical Center Institutional Animal Care and Use Committee and by the Ethical Committee for Animal Experiments of the Erasmus Medical Center in Rotterdam. The design was selected to allow comparison of the results with previously published data relating to the two genotypes (5,7).
Experimental Procedures
AB treatment. The CF mice and their respective WT littermates were individually housed. The experimental group received a 3-week (broad-spectrum) AB treatment (ciprofloxacin, 50 mg/kg/day and metronidazole, 100 mg/kg/day), as previously described (5) . AB were administered to the liquid diet of the CFTR-knockout mice and their WT littermates. For the homozygous ΔF508 mice and their WT littermates, AB were administered in the drinking water, which was refreshed on a daily basis. Because of the light sensitivity of ciprofloxacin, the drinking bottles were covered with aluminium foil. Prior to the administration of AB, the daily intakes of liquid diet and water per mouse were measured. Thereafter, the dose of AB required per mouse was calculated and added to ensure an equal AB dose, on average, for each of the mice. Addition of AB did not affect the drinking behavior of the mice.
Fat balance study. After 3 weeks of AB treatment, a 72-h fat balance test was performed. During the last 3 days of treatment, the amount of dietary intake was noted and feces collected. Fecal pellets were freezedried and mechanically homogenized. Lipids were extracted from the samples, hydrolyzed, and methylated in accordance with the procedure described by Muskiet et al. (22) . The resulting fatty acid methyl esters of LCFA were analyzed and quantified by gas chromatography, using heptadecanoic acid as an internal standard. The fat absorption coefficient (%) was calculated by subtracting the fecal fat output (g/day) from the fat intake (g/day), divided by the fat intake (g/day) multiplied by 100%.
Bile salt analysis. The total bile salt concentration was measured in an aliquot of feces (collected for the 3-day fat balance). In the homozygous ΔF508 mice and their WT littermates, the bile salt concentration was measured in gallbladder bile. After deconjugation, bile salt profiles were determined by extracting the bile salts with commercially available Sep-Pak-C18 (Mallinckrodt Baker, Deventer, The 
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Antibiotics and fat absorption in CF Netherlands) cartridges and converting them to their methylester/ trimethylsilyl derivatives (23) . Bile salt profiles were analyzed using capillary gas chromatography. The hydrophobicity of bile salts in gallbladder bile was calculated using the Heuman index, corresponding to the ability of bile salts to solubilize lipids (24) .
Kinetics of fat absorption. The rate of intestinal uptake of triglycerides and fatty acids labeled with stable isotopes was determined in homozygous ΔF508 mice and their WT littermates. After 3 weeks of AB or control treatment (after finishing the 3-day fecal collection for estimation of fat balance), the mice were intraperitoneally injected with 1 mg/kg poloxamer of 407 to block lipoprotein lipasedependent lipolysis (25) . Subsequently, a 100 µl bolus composed of olive oil (25%) and medium-chain triglyceride oil (75%) was intragastrically administered. This bolus contained 2 mg 13 C-labeled tripalmitin and 2 mg 13 C-labeled stearate per 30 g body weight. After bolus administration, the mice were deprived of food. Blood samples of ~75 µl were taken from the lateral tail vein before bolus administration and at 2, 4, and 6 h after bolus administration, using heparin-coated microhematocrit tubes. The mice were then killed by puncturing the heart. Plasma and erythrocytes were separated by centrifugation (2,000 r.p.m., 10 min at 4 °C). The plasma samples were derivatized to their α-bromopentafluorobenzyl esters, and 13 C-enrichment of 1-13 C-palmitin and 1-13 C-stearate was measured by gas chromatography combustion isotope ratio mass spectrometry (Delta S/GC Finnigan MAT, Bremen, Germany). 13 C-enrichment in plasma was calculated from the fatty acid concentration and expressed as the percentage of the administered dose/ml of plasma (% dose/ml). Total plasma triglyceride concentrations were determined using commercially available kits (Roche Diagnostics, Mannheim, Germany).
Bacterial load in the small intestine. After the mice were killed, the small intestine was flushed with phosphate-buffered saline containing 10 mmol/l DTT as a mucolytic agent. The eluent was centrifuged at 5,000 r.p.m. for 45 min to pellet the bacteria. Bacterial genomic DNA was isolated using the Qiagen DNA stool kit (Qiagen, Venlo, The Netherlands). Quantitative-PCR with an SYBR Green detection system (Bio-Rad MyIQ; Qiagen) was performed, using both group-specific and kingdom-specific primers (26, 27) . Kingdom-specific primers for 16S rDNA were used for the amplification of the total bacterial load, whereas group-specific primers were used for the quantification of each bacterial group. Each primer set was evaluated against reference bacterial strains for primer efficiency and specificity ( Table 6 ).
mRNA expression in the small intestine. Total RNA was isolated from the whole small intestine with TriReagent (Sigma, St Louis, MO), washed with an RNA cleanup kit (RNeasy MinElute Cleanup kit; Qiagen) and quantified using a NanoDrop ND100 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Relative mRNA expression for mucin 2 was determined using 5 µl cDNA. Primers for mucin 2 were kindly provided by I. Renes, and PCR was carried out as previously described (28) . PCR products were loaded on a 1% agarose gel and electrophoresed in a 1× tris-acetate-EDTA (TAE) buffer in the presence of ethidium bromide. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control.
Statistical analysis. Statistical analysis was performed using SPSS 16 .0 (SPSS, Chicago, IL). We calculated, with an anticipated coefficient of variation of 10%, a required sample size of four per group to demonstrate a 30% decrease in fat malabsorption as compared to WT animals. Differences between experimental and control groups were calculated using the Mann-Whitney test. Data are reported as mean values ± SD (SEM in figures) or as median (range) where the data were not normally distributed. P values <0.05 were considered statistically significant. To exclude possible gender-related differences in treatment effect, we performed an additional multiple-regression analysis. Parameters for fat absorption, fecal bile salt excretion, and weight were included as dependent variables, whereas genotype, treatment, gender, and the interaction variable gender × treatment were included as independent variables.
